08:55 AM EST, 12/02/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday it submitted two supplemental biologics license applications to the US Food and Drug Administration for Tremfya to treat children 6 years and older with moderate-to-severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.

The applications are supported by phase 3 trial data in pediatric plaque psoriasis patients and pharmacokinetic extrapolation data from adult studies, Johnson & Johnson ( JNJ ) said.

Tremfya, or guselkumab, is currently approved in the US to treat adults with moderate to severe plaque psoriasis or active psoriatic arthritis.